iDiagnostics - the handheld future of precision medicine; Single Molecule Detection, Single Cell Analysis, Cell Membrane Studies, TIRF microscopy, TIRF accessories for fluorometers, TIRF biosensor instruments, Real-time TIRF microarrays, and more>>> visit www.tirf-labs.com
Handheld Molecular iDiagnostics
by TIRF Labs
OPEN INNOVATION APPROACH
for collaborative development
of molecular diagnostic applications
If you are developing a molecular diagnostics (MDx) system based on fluorescence or electro-chemi-luminescence assays, we are offering to you an exciting opportunity to collaborate. We will help you with unique hardware, software, cartridge blanks, development tools, reagent kits, methods and protocols to facilitastics platform. We will be delighted to license your Intellectute the interfacing of your assays with advanced iDiagnoal Property (IP) and offer you the opportunity to license our IP to develop precise and rapid, yet affordable devices for molecular diagnosis and prognosis.
The iDiagnostics platform provides unprecedented precision and rapid diagnosing due to its superior sensitivity, multiplicity, and fast response rate. The platform is several orders of magnitude more sensitive and more accurate than traditional methods. One of the advantages of iDiagnostics involves simultaneous detection of multiple molecular markers of different classes, including proteins, nucleic acids, and metabolites. Detection of different classes of markers is necessary for minimization of the rate of false positive responses.
iDiagnostics employs 3D-encapsulated real-time TIRF microarrays that include internal controls and standards for normalization and calibration, which provides high reliability and broad dynamic range to iDiagnostics analyses. The platform also supports other luminescence assays, including Electro-Chemi-Luminescence (ECL). iDiagnostics integrates optics, microfluidics, electronics, electrochemical system, and nanoengineered assays into a small handheld device. Real-time TIRF microarrays are capable of parallel detecting up to thousands of analytes, including proteins, nucleic acids, toxins and chemical agents.
iDiagnostics requires no or minimal sample preparation and can analyze complex biological fluids, including whole blood, saliva, and urine. It employs reagentless bioassays based on molecular beacons and sandwich-format antibody-based assays. Typically, molecular markers are detected in several seconds or a few minutes after the sample is applied.
Applications for the iDiagnostics platform include early diagnosing of cancer, heart diseases, STD, influenza, other infectious diseases, food and water safety, biodefense, forensic, military, environmental, and agricultural analyses.
Our goal is to make accurate iDiagnostics available to every one. Open Innovation Approach, which we use in this project, is well suited for collaborative development of advanced diagnostic products. If you are interested to become a part of this exciting project please send us an email to <email@example.com>.
The Giving Pledge Opportunity in the Area of Molecular Diagnostics
Our goal is to make accurate iDiagnostics affordable to every family around the globe. At the initial stage, we will distribute uTIRF biodetection station and iDiagnostics Application Development Kit (ADK) to diagnostic research groups. In our lab in North Carolina we will develop tests for prostate and pancreatic cancer, food and water safety. We seek private and institutional donations, U.S. government and international grants for the initial stage - Phase 1.
TIRF Labs does Not pursue a commercial goal in iDiagnostics project, despite the fact that the market of molecular diagnostics is large and rapidly growing. We do not wish that iDiagnostics becomes one more expensive tool available only for small group of individuals. Our goal is to make accurate molecular diagnostics affordable, so that every family could afford to have it in their medical cabinet.
After 9/11 followed by anthrax letters attack, the U.S. government spent ~$80 Billion on biodefense. There is no analytical technique, which has not been tried for molecular diagnostics. However, all existing methods are inaccurate, slow, bulky, or too costly. The iDiagnostics platform is several orders of magnitude more accurate and rapid, yet affordable.
Social impact. iDiagnostics will change the paradigm of medicine; it will relocate the diagnosing from medical centers to individuals, make the diagnosing accurate, rapid, minimally invasive, and affordable for all. It will help to prevent spreading of infectious diseases and enable personalized medicine. Individuals will become the owners of information about their health; they will decide what to do with the diagnostic data - email them to a medical doctor or keep on their files for the future.
Open Innovation Approach. TIRF Labs offers to biodetection community research groups the iDiagnostics ADK and uTIRF detection station for development of diagnostic tests for medicine and for use in many other areas of lifesciences. We have received large response from the diagnostic community and will use the feedback to further advance iDiagnostics platform and methods. We will support our collaborators 24/7 to facilitate interfacing of bioassays, sample preparation, and data analysis. Applications for iDiagnostics platform include diagnosing and prognosing of cancer, heart diseases, infectious diseases, longevity studies, food and water safety, environmental and agricultural applications, preventative and counter-measures against bioterrorism and naturally occurring diseases.
iDiagnostics Cradles with iPhones
and Sensor Cartridges
Literature (Selected publications of our customers and our own data generated by TIRF Labs' products)
1. Asanov A. “TIRF-EC Biosensors Massively parallel DNA and Protein Microarrays for Accurate and Rapid Detection of Pathogens.” Biodetection Technologies 2007. Knowledge Press, Brookline, MA. 4th Edition, 2007, Chapter 17, p. 373-396, isbn # 1-59430-126-3.
2. Asanov A. “TIRF-EC Biosensors with Reagentless Bioassays for Rapid and Accurate Detection of Pathogens.” Biodetection Technologies 2008. Knowledge Press, Brookline, MA. 5th Edition, 2008, Chapter 8, p. 155-190, isbn # 1-59430-137-9.
3. Asanov A., Wilson W., and Oldham P. “Regenerable biosensor using total internal reflection fluorescence with electrochemical control”. US Patent 6,511,854. Publication Date: 2003-01-28. (Active patent.)
4. Asanov A., Zepeda A., Vaca L. “Combined DNA and Protein Microarrays Based on Total Internal Reflection Fluorescence.” Sensors, 2012, 12, 1800.
5. Patents pending 2016-2017.
6. Willoughby D., Everett K., Halls M., Pacheco J., Skroblin P., Vaca L., Klussmann E., and Cooper D. “Direct Binding Between Orai1 and AC8 Mediates Dynamic Interplay Between Ca2+ and cAMP Signaling.” Science Signaling, 2012, 5 (219), 29.
7. Sampieri A., Zepeda A., Asanov A., and Vaca L. “Visualizing the store operated channel complex assembly in real time: Identification of SERCA2 as a new member.” Cell Calcium, 2009, 45, 439.
8. Asanov A., Zepeda A., and Vaca L. “A novel form of Total Internal Reflection Fluorescence Microscopy (LG-TIRFM) reveals different and independent lipid raft domains in living cells.“ Biochim. Biophys. Acta, 2010, 1801, 147.
9. Asanov A, Sherry R, Sampieri A, and Vaca L. “A relay mechanism between EB1 and APC facilitate STIM1 puncta assembly at endoplasmic reticulum plasma membrane junctions”. Cell Calcium, 2013, 54, 246– 256
10. Luz-Madrigal A, Asanov A, Camacho-Zarco AR, Sampieri A, and Vaca L. “A Cholesterol Recognition Amino Acid Consensus Domain in GP64 Fusion Protein Facilitates Anchoring of Baculovirus to Mammalian Cells”. Journal of Virology, 2013, 87 (2), 11894–11907.
11. Additional publications of our customers with data generated by our TIRF and TIRF-EC products are available at the URL: www.tirf-labs.com
uTIRF Biodetection Station and iDiagnostics Application Development Kit
This page is under construction. Visit us soon